会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 3. 发明授权
    • Organonitro thioether compounds and medical uses thereof
    • 有机硝基硫醚化合物及其医疗用途
    • US09139519B2
    • 2015-09-22
    • US14349004
    • 2012-05-18
    • Jan ScicinskiBryan T. Oronsky
    • Jan ScicinskiBryan T. Oronsky
    • A61K31/397C07D205/04A61K31/19A61K31/198A61K31/215A61K31/337A61K45/06A61N5/10
    • A61K31/397A61K31/19A61K31/198A61K31/215A61K31/337A61K38/05A61K45/06A61N5/10C07D205/04
    • The invention provides organonitro thioether compounds, compositions containing such compounds, isolated organonitro thioether compounds and methods for using such compounds and compositions to treat cancer in a patient. Exemplary organonitro thioether compounds described herein include 2-(3,3-dinitroazetidin-1-yl)-2-oxoethyl thioethers and variants thereof. Another aspect of the invention provides a pharmaceutical composition, comprising a pharmaceutically acceptable carrier and an organonitro thioether compound described herein, such as a compound of Formula I or II. Another aspect of the invention provides a method of treating cancer in a patient. The method comprises administering to a patient in need thereof a therapeutically effective amount of an organonitro thioether compound described herein, such as a compound of Formula I or II, to treat the cancer.
    • 本发明提供有机硫醚化合物,含有这些化合物的组合物,分离的有机硫醚化合物和使用这些化合物和组合物治疗患者癌症的方法。 本文所述的示例性有机亚硫醚化合物包括2-(3,3-二硝基吖丁啶-1-基)-2-氧代乙基硫醚及其变体。 本发明的另一方面提供了药物组合物,其包含本文所述的药学上可接受的载体和有机硫醚化合物,例如式I或II的化合物。 本发明的另一方面提供了一种治疗患者癌症的方法。 该方法包括向有需要的患者施用治疗有效量的本文所述的有机硝基硫醚化合物,例如式I或II的化合物,以治疗癌症。
    • 5. 发明申请
    • ORGANONITRO THIOETHER COMPOUNDS AND MEDICAL USES THEREOF
    • ORGANONITRO THIOETHER化合物及其医疗用途
    • US20140349988A1
    • 2014-11-27
    • US14349004
    • 2012-05-18
    • Jan ScicinskiBryan T. Oronsky
    • Jan ScicinskiBryan T. Oronsky
    • C07D205/04A61K45/06A61N5/10A61K31/397
    • A61K31/397A61K31/19A61K31/198A61K31/215A61K31/337A61K38/05A61K45/06A61N5/10C07D205/04
    • The invention provides organonitro thioether compounds, compositions containing such compounds, isolated organonitro thioether compounds and methods for using such compounds and compositions to treat cancer in a patient. Exemplary organonitro thioether compounds described herein include 2-(3,3-dinitroazetidin-1-yl)-2-oxoethyl thioethers and variants thereof. Another aspect of the invention provides a pharmaceutical composition, comprising a pharmaceutically acceptable carrier and an organonitro thioether compound described herein, such as a compound of Formula I or II. Another aspect of the invention provides a method of treating cancer in a patient. The method comprises administering to a patient in need thereof a therapeutically effective amount of an organonitro thioether compound described herein, such as a compound of Formula I or II, to treat the cancer.
    • 本发明提供有机硫醚化合物,含有这些化合物的组合物,分离的有机硫醚化合物和使用这些化合物和组合物治疗患者癌症的方法。 本文所述的示例性有机亚硫醚化合物包括2-(3,3-二硝基吖丁啶-1-基)-2-氧代乙基硫醚及其变体。 本发明的另一方面提供了药物组合物,其包含本文所述的药学上可接受的载体和有机硫醚化合物,例如式I或II的化合物。 本发明的另一方面提供了一种治疗患者癌症的方法。 该方法包括向有需要的患者施用治疗有效量的本文所述的有机硝基硫醚化合物,例如式I或II的化合物,以治疗癌症。
    • 6. 发明授权
    • Formulation for decreasing tobacco, alcohol, drug or food consumption
    • 减少烟草,酒精,药物或食物消费的配方
    • US08784872B2
    • 2014-07-22
    • US11942414
    • 2007-11-19
    • Bryan T. OronskyNeil C. OronskyArnold L. Oronsky
    • Bryan T. OronskyNeil C. OronskyArnold L. Oronsky
    • A61K9/00A61K47/00A61K9/68A61K36/00A61K31/4168A61K9/12A61K9/70
    • A61K47/34A24B15/16A61K9/0056A61K9/08A61K47/02A61K47/32A61K47/36
    • Formulations have been developed which assist individuals having an addiction such as smoking to reduce or quit engaging in the addictive behavior. Representative behaviors include smoking, excessive alcohol or food ingestion, drug addiction, and ingestion of caffeine or junk food providing quick “highs”. The formulations assist the smoker to become dissatisfied with smoking, until he or she willingly gives up the habit or at least cuts down on the number of cigarettes smoked per day as an initial step towards quitting in the future. The formulations can also be used in conjunction with other known formulations, such as nicotine gum or patch. The formulations contain hydrophilic polymers, for example, polyethylene glycol (PEG) alone or in combination or polyvinyl pyrrolidone (PVP) (also known as povidone or polyvidone alone or in combination.), sweeteners and/or flavorings, viscosity modifiers/binders, and pH or buffering agents.
    • 已经开发了帮助患有吸烟等成瘾的个体减少或戒除上瘾行为的制剂。 代表性的行为包括吸烟,过度酒精或食物摄入,吸毒成瘾,以及摄取咖啡因或垃圾食品,提供快速“高”。 这些配方有助于吸烟者对吸烟不满意,直到他或她愿意放弃习惯,或者至少减少每天吸烟的香烟数量,作为今后戒烟的最初步骤。 制剂也可以与其它已知的制剂结合使用,例如尼古丁胶或贴剂。 制剂含有亲水性聚合物,例如单独使用或组合使用的聚乙二醇(PEG)或聚乙烯吡咯烷酮(PVP)(也称为聚维酮或聚维酮,单独或组合使用),甜味剂和/或调味剂,粘度调节剂/粘合剂和 pH或缓冲剂。